Alkermes drug is first long-acting atypical antipsychotic with both once-monthly and six-week dosing options
The US Food and Drug Administration (FDA) has approved Aristada (aripiprazole lauroxil), Alkermes' extended-release injectable suspension for the treatment of schizophrenia. Aristada is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body through an injection. Alkermes is preparing to launch Aristada immediately.
'Aristada is a new treatment option designed to offer flexibility to meet the real-world needs of patients suffering from schizophrenia and the healthcare professionals providing their care,' said Dr Elliot Ehrich, Chief Medical Officer of Alkermes. 'Building on nearly two decades of experience developing innovative medicines for chronic and serious CNS diseases, we are dedicated to helping to improve the lives of patients as well as meeting the needs within the treatment ecosystem of caregivers, physicians, payers and society. We look forward to making Aristada available to patients and healthcare providers as quickly as possible.'
Aristada's features, including a range of dose strengths and dosing interval options, are designed to address the individual needs of patients and challenges in the treatment of schizophrenia. As a long-acting injectable medicine, Aristada provides patients with blood concentrations of active drug that remain within a therapeutic range for an extended period of time and help healthcare providers to track patient adherence.
'Schizophrenia is a serious and debilitating disease where, despite the existence of many medicines, there remains significant unmet medical need and suffering. New treatment options are needed to help patients and their families better manage this illness,' said Dr David Henderson, Associate Professor of Psychiatry at Massachusetts General Hospital. 'Long-acting therapies are rapidly evolving to the forefront of the treatment of schizophrenia as clinicians increasingly recognise the potential benefits of less frequent dosing and consider their use earlier in disease progression.'
The FDA approval of Aristada was based on a proven safety and efficacy profile, including data from a randomised, double-blind, placebo-controlled, phase III study in 623 patients with schizophrenia. Data from that trial showed that multiple dose strengths of Aristada met the primary endpoint with statistically significant and clinically meaningful reductions in Positive and Negative Syndrome Scale (PANSS) total scores at Week 12, met the key secondary endpoint and demonstrated significant improvements in schizophrenia symptoms versus placebo. The most common adverse events in the study were insomnia, akathisia and headache. The results of the phase III study were published in June 2015 by The Journal of Clinical Psychiatry.